Table 3 Characteristics of the patients with axial spondyloarthritis stratified by calprotectin percentiles. All results are mean (with standard deviation), except those with an asterisk* which are median [with interquartile range], and those marked with a “§” which are number of patients (%). Abbreviations: BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, ASDAS Ankylosing Spondylitis Disease Activity Score
From: Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis
Serum calprotectin quartile [μg/ml] | 0–1.6 | 1.6–2.4 | 2.4–3.9 | 3.9–13 | p value |
|---|---|---|---|---|---|
n | 113 | 113 | 112 | 113 | Â |
Disease duration, years | 10.4 (10.2) | 8.5 (9.8) | 9.9 (9.8) | 10.6 (9.4) | 0.37 |
Age years | 45.9 (11.4) | 44.4 (12.7) | 43.0 (11.3) | 42.7 (13.7) | 0.20 |
Gender = male§ | 62 (54.9) | 62 (54.9) | 67 (59.8) | 77 (68.1) | 0.03 |
BMI kg/m2 | 25.3 (4.7) | 26.3 (4.8) | 26.3 (5.4) | 26.3 (4.7) | 0.44 |
ESR mm/h* | 6.0 [4.0, 11.5] | 8.0 [4.0, 17.5] | 8.0 [4.0, 16.0] | 10.0 [4.0, 25.0] | 0.01 |
CRP mg/l* | 3.0 [1.0, 8.0] | 2.0 [1.0, 8.0] | 3.0 [1.0, 8.0] | 4.0 [2.0, 13.0] | < 0.01 |
BASDAI score | 3.6 (2.3) | 4.0 (2.4) | 3.5 (2.4) | 4.1 (2.3) | 0.19 |
BASFI score | 2.1 (2.3) | 2.7 (2.6) | 2.3 (2.3) | 2.8 (2.5) | 0.22 |
ASDAS score | 2.1 (0.9) | 2.4 (1.0) | 2.2 (1.1) | 2.7 (1.0) | 0.01 |
ASDAS moderate/high§1 | 40/79 (50.6) | 47/81 (58.0) | 37/65 (56.9) | 49/72 (68.1) | 0.04 |
ASDAS remission§2 | 14/79 (17.7) | 16/81 (19.8) | 20/65 (30.8) | 4/72 (5.56) | 0.20 |
Physician global disease activity | 1.9 (1.6) | 2.4 (2.0) | 2.2 (2.0) | 2.6 (1.8) | 0.02 |
Swollen joint count | 0.4 (0.9) | 0.6 (1.8) | 0.4 (0.9) | 0.3 (1.2) | 0.46 |
Hip involvement§ | 3 (2.7) | 3 (2.7) | 5 (4.5) | 10 (8.8) | 0.02 |
Enthesitis§ | 32 (28.3) | 38 (33.6) | 40 (35.7) | 36 (31.9) | 0.68 |
Dactylitis§ | 2 (1.8) | 0 (0.0) | 5 (4.5) | 3 (2.7) | 0.51 |